| First Author | Liu Y | Year | 2024 |
| Journal | Int J Biol Sci | Volume | 20 |
| Issue | 13 | Pages | 5223-5238 |
| PubMed ID | 39430240 | Mgi Jnum | J:357573 |
| Mgi Id | MGI:7763131 | Doi | 10.7150/ijbs.99817 |
| Citation | Liu Y, et al. (2024) USP44 inactivation accelerates the progression of thyroid cancer by inducing ubiquitylation and degradation of p21. Int J Biol Sci 20(13):5223-5238 |
| abstractText | Ubiquitin-specific peptidase 44 (USP44) belongs to the ubiquitin-specific protease family and is pivotal in the development and progression of tumors across various human cancers. However, its biological function and the underlying mechanisms in thyroid cancer remain poorly understood. In this study, we observed that USP44 was frequently downregulated by promoter hypermethylation in thyroid cancers and found that its decreased expression was closely associated with poor patient survival. Subsequent in vitro and in vivo functional studies revealed that USP44 substantially suppressed the proliferation of thyroid cancer cells by impeding the G1/S transition in cell cycle. Mechanistically, USP44 directly interacted with p21 and eliminated its K-48-linked polyubiquitination chain, thereby stabilizing p21 proteins in a cell cycle-independent manner. In addition, the rescue of p21 partially alleviated cell cycle advancement and cell proliferation induced by the depletion of USP44. Our findings, taken together, indicate that USP44 is frequently repressed in thyroid cancer due to promoter hypermethylation and functions as a tumor suppressor by stabilizing p21 via deubiquitination. |
